Literature DB >> 27826372

Vascular Inflammation: A Novel Access Route for Nanomedicine.

Roberto Molinaro1, Christian Boada2, Guillermo Medrano Del Rosal1, Kelly A Hartman1, Claudia Corbo3, Elizabeth D Andrews1, Naama E Toledano-Furman1, John P Cooke1, Ennio Tasciotti4.   

Abstract

Despite an improved understanding of its pathophysiology and a wide range of new treatments, cardiovascular disease (CVD) remains a serious public health issue and the number one cause of mortality in the United States. Conditions that promote chronic systemic inflammation, such as obesity, cancer, and autoimmune and infectious diseases, are now known to play an important role in promoting CVD by inducing the expression of endothelial adhesion molecules and chemokines; these in turn promote leukocyte adherence and infiltration, which initiates and spurs the progression of CVD. In response to this new understanding, researchers are evaluating the potential cardiovascular benefits of new-generation therapies based on endogenous molecules with anti-inflammatory properties. Similarly, targeted approaches that leverage the phenotypic differences between non-inflamed and inflamed endothelia have the potential to selectively deliver therapeutics and decrease the morbidity and mortality of CVD patients. In this review, we discuss the role of inflammation in CVD and explore the therapeutic potential of targeting inflamed vasculature through conventional and biomimetic approaches.

Entities:  

Keywords:  C-reactive protein; NF-kB; cardiovascular diseases; drug delivery platform; endotheliopathies; endothelium; statins; theranostic; vascular inflammation

Mesh:

Substances:

Year:  2016        PMID: 27826372      PMCID: PMC5098575          DOI: 10.14797/mdcj-12-3-169

Source DB:  PubMed          Journal:  Methodist Debakey Cardiovasc J        ISSN: 1947-6108


  46 in total

Review 1.  Flow, NO, and atherogenesis.

Authors:  John P Cooke
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-27       Impact factor: 11.205

2.  Visceral obesity and plasma glucose-insulin homeostasis: contributions of interleukin-6 and tumor necrosis factor-alpha in men.

Authors:  Amélie Cartier; Isabelle Lemieux; Natalie Alméras; Angelo Tremblay; Jean Bergeron; Jean-Pierre Després
Journal:  J Clin Endocrinol Metab       Date:  2008-03-04       Impact factor: 5.958

Review 3.  The vessel wall and its interactions.

Authors:  Denisa D Wagner; Paul S Frenette
Journal:  Blood       Date:  2008-06-01       Impact factor: 22.113

Review 4.  Targeted therapeutics and nanodevices for vascular drug delivery: quo vadis?

Authors:  Vladimir R Muzykantov
Journal:  IUBMB Life       Date:  2011-06-30       Impact factor: 3.885

5.  Targeted Nanocarriers for Imaging and Therapy of Vascular Inflammation.

Authors:  Ann-Marie Chacko; Elizabeth D Hood; Blaine J Zern; Vladimir R Muzykantov
Journal:  Curr Opin Colloid Interface Sci       Date:  2011-06       Impact factor: 6.448

6.  LipoCardium: endothelium-directed cyclopentenone prostaglandin-based liposome formulation that completely reverses atherosclerotic lesions.

Authors:  Paulo I Homem de Bittencourt; Denise J Lagranha; Alexandre Maslinkiewicz; Sueli M Senna; Angela M V Tavares; Lisiane P Baldissera; Daiane R Janner; Joelso S Peralta; Patrícia M Bock; Lucila L P Gutierrez; Gustavo Scola; Thiago G Heck; Maurício S Krause; Lavínia A Cruz; Dulcinéia S P Abdalla; Cláudia J Lagranha; Thais Lima; Rui Curi
Journal:  Atherosclerosis       Date:  2006-09-25       Impact factor: 5.162

Review 7.  Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.

Authors:  Min Jun; Celine Foote; Jicheng Lv; Bruce Neal; Anushka Patel; Stephen J Nicholls; Diederick E Grobbee; Alan Cass; John Chalmers; Vlado Perkovic
Journal:  Lancet       Date:  2010-05-10       Impact factor: 79.321

8.  Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields.

Authors:  Michael Chorny; Ilia Fishbein; Benjamin B Yellen; Ivan S Alferiev; Marina Bakay; Srinivas Ganta; Richard Adamo; Mansoor Amiji; Gary Friedman; Robert J Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-04-19       Impact factor: 11.205

9.  Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Authors:  Alessandro Parodi; Nicoletta Quattrocchi; Anne L van de Ven; Ciro Chiappini; Michael Evangelopoulos; Jonathan O Martinez; Brandon S Brown; Sm Z Khaled; Iman K Yazdi; Maria Vittoria Enzo; Lucas Isenhart; Mauro Ferrari; Ennio Tasciotti
Journal:  Nat Nanotechnol       Date:  2012-12-16       Impact factor: 39.213

Review 10.  Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.

Authors:  Melissa Howard; Blaine J Zern; Aaron C Anselmo; Vladimir V Shuvaev; Samir Mitragotri; Vladimir Muzykantov
Journal:  ACS Nano       Date:  2014-05-07       Impact factor: 15.881

View more
  6 in total

Review 1.  Personalized protein corona on nanoparticles and its clinical implications.

Authors:  Claudia Corbo; Roberto Molinaro; Mateen Tabatabaei; Omid C Farokhzad; Morteza Mahmoudi
Journal:  Biomater Sci       Date:  2017-02-28       Impact factor: 6.843

Review 2.  Theranostic Nanomedicines for the Treatment of Cardiovascular and Related Diseases: Current Strategies and Future Perspectives.

Authors:  Natasha Manners; Vishnu Priya; Abhishesh Kumar Mehata; Manoj Rawat; Syam Mohan; Hafiz A Makeen; Mohammed Albratty; Ali Albarrati; Abdulkarim M Meraya; Madaswamy S Muthu
Journal:  Pharmaceuticals (Basel)       Date:  2022-04-01

3.  Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug delivery.

Authors:  Jonathan O Martinez; Roberto Molinaro; Kelly A Hartman; Christian Boada; Roman Sukhovershin; Enrica De Rosa; Dickson Kirui; Shanrong Zhang; Michael Evangelopoulos; Angela M Carter; James A Bibb; John P Cooke; Ennio Tasciotti
Journal:  Theranostics       Date:  2018-01-05       Impact factor: 11.556

Review 4.  Nanoparticle Platforms for Antigen-Specific Immune Tolerance.

Authors:  Edward B Thorp; Christian Boada; Clarens Jarbath; Xunrong Luo
Journal:  Front Immunol       Date:  2020-05-20       Impact factor: 7.561

Review 5.  Advancement of nanomedicines in chronic inflammatory disorders.

Authors:  Vikas Jogpal; Mohit Sanduja; Rohit Dutt; Vandana Garg
Journal:  Inflammopharmacology       Date:  2022-02-25       Impact factor: 5.093

Review 6.  Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases.

Authors:  Nura A Mohamed; Isra Marei; Sergio Crovella; Haissam Abou-Saleh
Journal:  Int J Mol Sci       Date:  2022-01-26       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.